Related Experiment Videos
Midazolam daytime residual effect evaluated by the Multiple Sleep Latency Test
1Sleep Disorders Center, Hospital Albert Einstein, University of São Paulo Medical School, Brasil.
Arquivos De Neuro-Psiquiatria
|June 1, 1993
Summary
A single dose of midazolam (a hypnotic) did not cause significant daytime sleepiness in healthy volunteers compared to placebo. The Multiple Sleep Latency Test (MSLT) showed no discernible differences in sleep latency following midazolam administration.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Trials
Background:
- Midazolam is a commonly prescribed hypnotic medication.
- Assessing residual daytime sleepiness after hypnotic use is crucial for patient safety.
- Quantitative methods are needed to evaluate the objective impact of hypnotics on alertness.
Purpose of the Study:
- To quantitatively assess daytime sleepiness after a single oral dose of midazolam.
- To compare the effects of midazolam versus placebo on sleep latency using the Multiple Sleep Latency Test (MSLT).
Main Methods:
- A double-blind, placebo-controlled study involving 20 healthy volunteers.
- Participants received either 15 mg oral midazolam or placebo at bedtime.
- Daytime sleepiness was evaluated the following day using clinical assessment, subjective checklists, and the MSLT at multiple time points.
Main Results:
- No significant differences in mean sleep latencies were detected between the midazolam and placebo groups across all MSLT assessments.
- Clinical evaluations and subjective symptom checklists also failed to reveal significant differences between the groups.
- Demographic data (age, sex, weight) were comparable between the midazolam and placebo groups.
Conclusions:
- A single 15 mg oral dose of midazolam did not produce detectable residual daytime sleepiness in healthy volunteers when assessed by the MSLT.
- These findings suggest that, under the studied conditions, midazolam may not significantly impair objective measures of alertness the day after administration.